CD8A and neoplasm: The combination of anti-PD-1 inhibitory and anti-OX40 agonist antibodies reduces the proportion of T-regulatory and exhausted T cells in PDAC and increases numbers of memory CD4+ and CD8+ T cells, eradicating all detectable tumor.